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Abstract Left ventricular hypertrophy (LVH) is a car-
diovascular complication highly prevalent in patients with
chronic kidney disease (CKD) and end-stage renal disease.
LVH in CKD patients has generally a negative prognostic
value, because it represents an independent risk factor for
the development of arrhythmias, sudden death, heart failure
and ischemic heart disease. LVH in CKD patients is sec-
ondary to both pressure and volume overload. Pressure
overload is secondary to preexisting hypertension, but also
to a loss of elasticity of the vessels and to vascular calci-
fications, leading to augmented pulse pressure. Anemia and
the retention of sodium and water secondary to decreased
renal function are responsible for volume overload, deter-
mining a hyperdynamic state. In particular, the correction
of anemia with erythropoietin in CKD patients is advan-
tageous, since it determines LVH reduction. Other risk
factors for LVH in CKD patients are documented: some are
specific to CKD, as mineral metabolism disorders (hypo-
calcemia, hyperphosphatemia, low serum vitamin D levels
and secondary hyperparathyroidism), others are non-tradi-
tional, such as increased asymmetric dimethylarginine,
oxidative stress, hyperhomocysteinemia and endothelial
dysfunction that, in turn, accelerates the process of ath-
erogenesis, triggers the inflammation and pro-thrombotic
state of the glomerular and the vascular endothelium and
aggravates the process of both CKD and LVH.
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Hypertension and CKD
About 3% of the adult population in the United States have
an elevated serum creatinine and 70% of these subjects
have hypertension [1]. Among people with ESRD, hyper-
tension is even more prevalent, reaching 86% [2]. Hyper-
tension and CKD are tightly related by a two-way
relationship. Hypertension is the second most prevalent
cause of renal impairment and ESRD [3]. Although only a
small percentage of patients with hypertension will develop
CKD [4], this population is expected to increase with the
increased prevalence of hypertension in the next decade [5].
Moreover, high blood pressure is a major promoter of the
decline in glomerular filtration rate (GFR) in patients with
established diabetic and non-diabetic kidney disease [6].
On the other hand, the development of CKD is per se a
cause of secondary hypertension and can worsen a preex-
isting hypertension increasing the incidence of resistant
hypertension [7, 8]. Despite a higher treatment rate in
comparison with hypertensive people without comorbidi-
ties, only a small percentage (23.2–42.2%) of CKD patients
have their hypertension controlled [9]. It is now well
established that people with CKD are several times more
likely to die from cardiovascular causes than those without
CKD [10]. A major component of this cause–effect rela-
tionship can be safely attributable to development of
hypertension and its complications [6]. Therefore, treat-
ment of hypertension is the most important lifesaving
intervention in the management of all forms of CKD, and
last World Kidney Day 2009 was dedicated to this key
issue [11].
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Hypertension-induced renal damage
Although progression to ESRD is a quite rare event in the
natural history of essential hypertension, mild renal dys-
function frequently occurs. This condition, defined as a
GFR \60 ml/min and/or the presence of micro- or mac-
roalbuminuria, even in the presence of serum creatinine in
the normal range, has a prevalence varying from 10 to 40%
[12–14]. Mild renal dysfunction does not necessarily imply
progression toward end-stage renal disease, but it rather
contributes to cardiovascular risk, being associated with a
3-times higher incidence of fatal events, regardless of other
common risk factors [12]. In the Framingham study,
patients with mild renal dysfunction showed an almost
2-times higher prevalence of coronary heart disease, con-
gestive heart failure, ischemic stroke and LVH when
compared with control subjects, even if the association of
renal dysfunction with cardiovascular events was lost after
adjustment for cardiovascular risk factors, including blood
pressure [15]. However, in the non-hypertensive, non-
diabetic individuals of the Framingham study, a microal-
buminuria above the median value was associated with a
rate of incident cardiovascular events of 8.8% in 10 years
compared with a 2.9% rate in individuals with microal-
buminuria below the median value [16].
The pathophysiological mechanisms underlying this
association have not yet been fully clarified. Leoncini and
coauthors demonstrated that mild renal dysfunction is
associated with subclinical end-organ damage, such as
LVH and carotid atherosclerosis, in a population of
untreated patients with primary hypertension and normal
serum creatinine levels [17]. Thus, the presence of target
organ damage such as LVH could represent an intermedi-
ate link between renal dysfunction and cardiovascular
events in all phases of the progression of renal failure,
starting from the earliest stages.
Genesis of hypertension in CKD
Genesis of hypertension in chronic kidney disease is mul-
tifactorial. The traditional mechanisms relate hypertension
to volume overload or to excessive activation of the renin–
angiotensin-aldosterone system (RAAS) in relation to the
state of sodium/volume balance [8]. Since interventions
directed only to normalize body fluid volume and to
antagonize RAAS often fail to reduce blood pressure, new
mechanisms have been hypothesized.
Multiple mechanisms, for example, renal ischemia or
activation of NAD(P)H oxidases by intrarenal RAAS can
increase oxidative stress in CKD. Reactive oxygen species
are important signaling molecules promoting vascular
smooth muscle cell growth and migration, endothelial
dysfunction and activation, and modification of the extra-
cellular matrix. Oxidative stress in CKD can also impair
dimethylarginine dimethylaminohydrolase activity, leading
to accumulation of asymmetric dimethylarginine (ADMA),
an endogenous inhibitor of nitric oxide synthesis that
promotes endothelial dysfunction [18]. Furthermore, renal
ischemia, via RAAS activation, production of reactive
oxygen species or through stimulation of renal afferences
from kidneys to central nervous system, is able to increase
sympathetic nervous system activity, thus altering blood
pressure autonomic regulation and promoting hypertension
[19]. Also, ADMA accumulation seems to be related to
sympathetic activation in CKD, representing another pos-
sible mechanism of blood pressure raising [20].
Endothelin (ET)-1 is a potent systemic and renal vaso-
constrictor, capable to induce inflammation, endothelial
dysfunction, arterial stiffness, vascular and cardiac hyper-
trophy [21]. ET-1 concentrations are increased and intra-
renal ET system is activated in CKD: thus, ET could be
involved in genesis of hypertension and increased cardio-
vascular risk in CKD [21].
Finally, erythropoietin, a cornerstone in treatment of
anemia associated with CKD, can frequently cause
hypertension [22]. The effect is largely independent of
changes in red blood cell mass or viscosity and possibly
related to increased release of ET-1 and increased norad-
renergic sensitivity [22].
Reactive oxygen species, endothelium-derived sub-
stances, RAAS and sympathetic activation, can induce
modifications in large artery function and structure, that
seriously affect blood pressure in CKD patients. Moreover,
arterial elastic properties are further altered by calcifications
of the arterial wall, frequently identified in uremic patients
[23, 24]. In this regard, it is generally accepted that vascular
calcification in uremic patients is localized predominantly
in the tunica media of the artery [25]. However, athero-
sclerotic plaques tend to be calcified, especially in advanced
atherosclerosis [26]. Therefore, arterial calcification in
patients with ESRD is the sum of intimal (atherosclerotic)
and medial calcification. Vascular calcification in CKD and
ESRD patients can worsen aortic stiffness [27], which is the
primary cause of increased systolic and pulse pressure in
CKD patients, whereas diastolic pressure decreases as
arterial stiffness increases. As pulse wave velocity increa-
ses, transmission velocity of both forward and backward
travelling waves increases, which causes the reflected wave
to arrive earlier in the central aorta and augments pressure
in late systole [28]. In CKD patients, systolic and pulse
blood pressures are stronger predictors of stroke, coronary
heart disease, myocardial infarction, heart failure and car-
diovascular mortality than diastolic pressure [6, 29]. Fur-
thermore, diastolic pressure is inversely related to coronary
heart disease and cardiovascular mortality [6, 29].
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LVH in CKD
LVH has a prevalence of approximately 40% in patients
with chronic kidney disease (CKD), and it progressively
increases with CKD progression until to 75% in ESRD
patients [30–32]. LVH is the strongest independent pre-
dictor of cardiovascular mortality in CKD patients [33],
and several factors including hypertension, hypervolemia,
anemia, increased neuro-hormone activation, secondary
hyperparathyroidism (SHPT) and mineral metabolism dis-
orders are implicated in the development of LVH [34].
Many factors influence left ventricular geometry in
CKD patients. Abnormal arterial stiffness and systolic
hypertension opposing left ventricular ejection cause a
pressure afterload, with development of concentric LVH.
Moreover, arterial stiffness causes an increase in myocar-
dial oxygen consumption and a decrease in myocardial
perfusion pressure, which may induce an imbalance in the
supply–demand ratio, with secondary coronary reserve
reduction (Fig. 1). Additionally, CKD is associated with
excess parathyroid hormone and reduced vitamin D levels
that are also likely to contribute to concentric myocardial
hypertrophy. Conversely, hypervolemia and chronic ane-
mia, causing an excessive volume load, are the principal
factors contributing to the development of eccentric LVH
[32]. In summary, CKD patients are faced with both
pressure- and volume overload states. However, sustained
overload in combination with CKD-associated factors such
as SHPT, RAAS activation and anemia may result in
maladaptive LVH [35] until the final picture of uremic
cardiomyopathy, characterized by structural changes in the
myocardium, such as collagen accumulation, cardiac cel-
lular apoptosis, fibrosis and calcification, resulting in sys-
tolic and diastolic dysfunction [34, 36, 37] (Fig. 2).
SHPT, mineral metabolism disorders and LVH
SHPT occurs in most patients during the progression
of CKD and it is secondary to hypocalcemia, deriving
from reduced synthesis of 1,25-dihydroxyvitamin D
(1,25OH-D3) in the kidney. Both low 1,25OH-D3 and
SHPT with their metabolic consequences—high serum
phosphate and calcium x phosphate (Ca x P) product—are
associated not only with bone loss but also with cardio-
vascular complications (vascular calcification and LVH)
[38, 39] and events (myocardial infarction and congestive
heart failure) [40]. Moreover, a direct mechanism of car-
diotoxicity of PTH has been postulated. In fact, PTH in
excess, acting as uremic toxin and ionophore agent, facil-
itates the entry of calcium ions within the vascular and
cardiac myocytes. Hence, the intracellular calcium over-
load, by increasing myocyte contractility, can directly
promote, on one hand, an increase in vascular reactivity,
with secondary augmented peripheral vascular resistance
and hypertension and, on the other hand, can cause cardiac
hypertrophy [39] and fibrosis [41] and cardiomyopathy
[42]. In hemodialysis patients with SHPT, intravenous
calcitriol administration was associated with a significant
reduction in PTH concentration, left ventricular mass and
wall thickness [43]. However, 1,25OH-D3 seems to play a
non-secondary role in the pathogenesis of cardiovascular
disease in CKD, independently from its calciotropic effect.
Experimental studies showed that active vitamin D regu-
lates cardiomyocyte proliferation and hypertrophy [44],
improves cardiac function and induces left ventricular
hypertrophy regression in patients with ESRD [45, 46].
Moreover, 1,25OH-D3 is a negative regulator of the renin-
angiotensin system [47] and might be involved in the
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Fig. 1 Relationship between the changes in arterial wall, blood
pressure, coronary perfusion and cardiac remodeling in CKD patients.
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Fig. 2 Concurrent pathogenic factors that contribute to the adaptive
LV remodeling process in relation to the progression of CKD, until to
the uremic cardiomyopathy. SHPT secondary hyperpathyroidism;
RAA renin-angiotensin-aldosterone; LVH left ventricular hypertrophy;
CKD chronic kidney disease; CV cardiovascular
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pathogenesis of hypertension and hypertension-associated
cardiac and arterial disorders [48]. Low 1,25OH-D3 serum
levels are independently associated with endothelial dys-
function, arterial stiffness and vascular calcifications in
hemodialysis patients [49]. Vascular calcification is a
strong prognostic marker of cardiovascular disease mor-
tality in CKD patients. Vascular calcification has long been
considered to be a passive, degenerative, and end-stage
process of atherosclerosis and inflammation. However,
recent evidence indicates that bone matrix proteins such as
osteopontin, matrix Gla protein (MGP) and osteocalcin are
expressed in calcified atherosclerotic lesions, and that
calcium-regulating hormones such as vitamin D3 and
parathyroid hormone-related protein regulate vascular
calcification in vitro. These findings suggest that vascular
calcification is an actively regulated process similar to
osteogenesis, and that bone-associated proteins may be
involved in the development of vascular calcification. The
pathogenesis of vascular calcification in CKD is not well
understood and is almost multifactorial. In CKD patients,
several studies have found associations of both traditional
risk factors, such as hypertension, hyperlipidemia and
diabetes, and uremic-specific risk factors with vascular
calcification. Most patients with progressive CKD develop
hyperphosphatemia. An elevated phosphate level is an
important risk factor for the development of calcification
and cardiovascular mortality in CKD patients. Thus, it is
hypothesized that an important regulator of vascular cal-
cification is the level of inorganic phosphate that directly
regulates human smooth muscle cell calcification through a
sodium-dependent phosphate transporter mechanism. After
treatment with elevated phosphate, there is a loss of smooth
muscle lineage markers, such as alpha-actin and SM-22
alpha, and a simultaneous gain of osteogenic markers such
as cbfa-1 and osteocalcin, and synthesis of matrix vesicles
and collagen-rich extracellular matrix [50] (Fig. 3). Ele-
vated phosphate may directly stimulate smooth muscle
cells to undergo phenotypic changes that predispose to
calcification and offer a novel explanation of the phe-
nomenon of vascular calcification under hyperphospha-
temic conditions, such as in CKD patients.
Anemia and LVH
Anemia is highly prevalent in CKD and may potentiate the
adverse effects of LVH on cardiovascular outcomes. In
fact, in the presence of anemia, volume overload occurs as
a physiological adaptation to the reduced oxygen delivery.
The heart attempts to compensate volume overload,
increasing left ventricular mass and assuming an eccentric
geometry. However, as cardiac hypertrophy progresses,
capillary density decreases, so may result a maladaptive
remodeling with reduced subendocardial perfusion and
myocardial fibrosis [32, 51]. Therefore, further subendo-
cardial ischemia increases the susceptibility to cardiac
events and to uremic cardiomyopathy. Anemia can lead to
progressive cardiac damage as well as progressive renal
damage. Correction of the anemia with erythropoietin and,
as necessary, intravenous iron may prevent the deteriora-
tion of both the heart and the kidneys. There is a triangular
relationship, a vicious circle, between heart failure, CKD
and anemia where each of these three can be both cause
and caused by the other [52]. In this regard, it has been
found in a group of CKD patients a significant negative
correlation between the drop in hemoglobin and increase in
LVMI, in the sense that, for any loss of 1 g/100 ml of
hemoglobin, an increase of 20 g/m2 of left ventricular mass
index (LVMI) is expected. Moreover, there appears to be
an amplification effect of decline in hemoglobin and GFR
on LVMI growth. In fact, when the loss of 1 g/100 ml of
hemoglobin is associated with a reduction in GFR of
10 ml/min, an increase of 30 g/m2 of LVMI is expected
[53]. Furthermore, the combination of anemia and LVH in
CKD identifies a population at greater risk for myocardial
infarction, stroke and death [54]. Indeed, the unfavorable
outcome in patients with both CKD and LVH, whose
survival is reduced and incidence of fatal and non-fatal CV
events increased, can be reversed if LVH is regressed by
therapy. Interventional studies have shown that partial
correction of anemia through erythropoietin, together with
an arterial hypertension successful therapy through RAAS
blockers such as ACE-inhibitors or sartans, was able to
induce LVH regression in CKD [55].
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Fig. 3 Effects of hyperphosphatemia in human smooth muscle cells
on the synthesis of osteogenic markers and calcium-binding proteins
involved in the vascular calcification. (Pit1: Na ? -phosphate (Pi)
cotransporter; Cbfa-1 Core-binding factor alpha 1; AP alkaline
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Conclusions
CKD is associated with increased cardiovascular risk.
LVH, together with coronary artery disease, has been
considered the main target of intervention. LVH is highly
prevalent in CKD even in early stages, when compared to
general non-selected population. This is mainly due to the
multifactorial pathogenesis of LVH in renal patients where
both hemodynamic and non-hemodynamic stimuli syner-
gically act inducing either an increase in left ventricular
mass, according to a concentric or eccentric pattern, until
to the final scene of uremic cardiomyopathy (Fig. 4).
Arterial hypertension and anemia, associated with mineral
metabolism abnormalities, seem to be the most important
factors. The most promising strategy in CKD seems to be
LVH early diagnosis, the correct screening of risk factors,
as well as starting treatment in the early stages renal fail-
ure, with the aim of improving general and cardiovascular
prognosis for CKD patients.
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